Data from single case reports and small series of mastocytosis patients treated with imatinib prompted the U.S. Food and Drug Administration (FDA) to approve in 2006 its use in adults with ASM lacking the D816V KIT mutation or with unknown KIT mutational status. Here, KIT is linked to mastocytosis.